NCT00412373 - Evaluation of Effectiveness and Safety of Flexible-dose Paliperidone Extended Release in Patients With Schizoaffective Disorder. | Biotech Hunter

Enrollment

307

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

June 30, 2008

Study Completion Date

June 30, 2008

Conditions

Schizoaffective DisorderPsychotic Disorder

Interventions

DRUG

Placebo

for 6 weeks

DRUG

Paliperidone ER

(3-12mg/day in 3 mg/day increments for 6 weeks)

DRUG

Paliperidone ER

(3-12mg/day in 3 mg/day increments for 6 weeks)

Trial Locations (44)

Unknown

Cerritos

Costa Mesa

Garden Grove

Huntington Beach

Pico Rivera

San Diego

Aventura

Hollywood

Kissimmee

Leesburg

Oklahoma City

Philadelphia

Charleston

Austin

Irving

Ahmedabad

Ahmedibad

Aurangabad

Chennai

Delhi

Kanpur Uttarpradeh

Pune

Vadadora

Ipoh

Kota Kinabalu

Kuala Lumpur

Kuching

Davao City

Mandaluyong

Manila

Pasig National Capitol Region

Arad

Bucharest

Câmpina

Com Gura Ocnitei

Iași

Piteşti

Daegu

Gyeonggi-do

Inchun

Jeonju

Kwangiu

Pusan

Seoul

All Listed Sponsors

collaborator

Janssen, LP

INDUSTRY

lead

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

INDUSTRY